Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Urology
- Screening for prostate cancer: systematic review and meta-analysis of randomized controlled trials.BMJ. 2010; 341: c4543
- Cancer statistics, 2010.CA Cancer J Clin. 2010; 60: 277-300
- Cancer statistics, 2011.CA Cancer J Clin. 2011; 61 (Available from:): 212-236
- National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program, Prostate Cancer Fact Sheet.(Available at:)Accessed June 9, 2015)
- Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.J Natl Cancer Inst. 2003; 95 (Available from:): 868-878
- Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends.J Natl Cancer Inst. 2002; 94 (Available from:): 981-990
- Prostate cancer, version 2.2014.J Natl Compr Canc Netw. 2014; 12: 686-718
- Radical prostatectomy versus observation for localized prostate cancer.N Engl J Med. 2012; 367: 203-213
- Screening for prostate cancer: U.S. preventive services task force recommendation statement.Ann Intern Med. 2012; 157 (Available from:): 120-134
- Expanding use of active surveillance: data from the national prostate cancer register (NPCR) of Sweden.J Urol. 2015; 193 (Available from:) (Supplement): e512
- The quality of health care delivered in adults in the United States.N Engl J Med. 2003; 348: 2635-2645
- Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer.J Urol. 2011; 186: 844-849
- Active surveillance for prostate cancer compared with immediate treatment.Cancer. 2012; 118: 3512-3518
- Urologists' use of intensity-modulated radiation therapy for prostate cancer.New Engl J Med. 2013; 369: 1629-1637
- Time trends and local variation in primary treatment of localized prostate cancer.J Clin Oncol. 2010; 28: 1117-1123
- Physician variation in management of low-risk prostate cancer: a population-based cohort study.JAMA Intern Med. 2014; 174 (Available from:): 1450-1459
- Increasing use of observation among men at low risk for prostate cancer mortality.J Urol. 2015; 193: 801-806
- Variation in prostate cancer care.JAMA. 2015; 313: 2066-2067
- Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy.J Urol. 2010; 183: 963-968
- Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom.Surg Oncol. 2002; 11: 3-11
- Limitations of claims and registry data in surgical oncology research.Ann Surg Oncol. 2008; 15: 415-423
- The power and the peril of large administrative databases.J Urol. 2015; 194: 10-11
Financial Disclosure: Dr. Franklin Gaylis is an owner of GenIT (which owns WizMDTM) and a consultant for Janssen Pharmaceuticals and Sanofi; he is also the recipient of study grants from Bayer and Janssen. Renee Calabrese and Dr. Edward Cohen are also owners of GenIT. Dr. Paul Dato is an owner of GenIT and a consultant for Astellas Pharma. Dr. Christopher J. Kane is a consultant for Astellas and Janssen Pharmaceuticals. The remaining author declares that she has no relevant financial interests.
Funding Support: This research was funded by Genesis Healthcare Partners in collaboration with the Department of Urology, UC San Diego Health.